Kenji Ikeda

Summary

Country: Japan

Publications

  1. ncbi Prediction model of hepatocarcinogenesis for patients with hepatitis C virus-related cirrhosis. Validation with internal and external cohorts
    Kenji Ikeda
    Department of Gastroenterology, Okinaka Memorial Institute for Medical Research, Toranomon Hospital, Toranomon 2 2 2, Minato ku, Tokyo 105 8470, Japan
    J Hepatol 44:1089-97. 2006
  2. ncbi Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    J Med Virol 79:1686-95. 2007
  3. ncbi Interferon-induced prolonged biochemical response reduces hepatocarcinogenesis in hepatitis C virus infection
    Yasuji Arase
    Department of Hepatology, Toranomon Hospital, Toranomon, Minato ku, Tokyo, Japan
    J Med Virol 79:1485-90. 2007
  4. ncbi A long-term glycyrrhizin injection therapy reduces hepatocellular carcinogenesis rate in patients with interferon-resistant active chronic hepatitis C: a cohort study of 1249 patients
    Kenji Ikeda
    Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    Dig Dis Sci 51:603-9. 2006
  5. ncbi Substitution of amino acid 70 in the hepatitis C virus core region of genotype 1b is an important predictor of elevated alpha-fetoprotein in patients without hepatocellular carcinoma
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    J Med Virol 80:1354-62. 2008
  6. ncbi A matched case-controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan: amino acid substitutions in HCV core region as predictor of sustained virological response
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    J Med Virol 81:452-8. 2009
  7. ncbi Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C
    Yasuji Arase
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Hepatology 49:739-44. 2009
  8. ncbi Clinicopathological features, background liver disease, and survival analysis of HCV-positive patients with hepatocellular carcinoma: differences between young and elderly patients
    Hiromi Saneto
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    J Gastroenterol 43:975-81. 2008
  9. ncbi Prediction of response to pegylated interferon and ribavirin in hepatitis C by polymorphisms in the viral core protein and very early dynamics of viremia
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Intervirology 50:361-8. 2007
  10. ncbi Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy
    Norio Akuta
    Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    Intervirology 48:372-80. 2005

Collaborators

Detail Information

Publications105 found, 100 shown here

  1. ncbi Prediction model of hepatocarcinogenesis for patients with hepatitis C virus-related cirrhosis. Validation with internal and external cohorts
    Kenji Ikeda
    Department of Gastroenterology, Okinaka Memorial Institute for Medical Research, Toranomon Hospital, Toranomon 2 2 2, Minato ku, Tokyo 105 8470, Japan
    J Hepatol 44:1089-97. 2006
    ..To estimate hepatocarcinogenesis rates in patients with hepatitis C virus (HCV)-related cirrhosis, an accurate prediction table was created...
  2. ncbi Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    J Med Virol 79:1686-95. 2007
    ..This study identified predictors of efficacy of PEG-IFN-RBV therapy based on viral kinetics in Japanese patients infected with HCV genotype 1b...
  3. ncbi Interferon-induced prolonged biochemical response reduces hepatocarcinogenesis in hepatitis C virus infection
    Yasuji Arase
    Department of Hepatology, Toranomon Hospital, Toranomon, Minato ku, Tokyo, Japan
    J Med Virol 79:1485-90. 2007
    ..026). The relative risk of HCC development in patients with BR was 0.36 compared with patients without BR. The attainment of BR during IFN therapy is effective in reducing hepatocarcinogenesis for patients with chronic HCV infection...
  4. ncbi A long-term glycyrrhizin injection therapy reduces hepatocellular carcinogenesis rate in patients with interferon-resistant active chronic hepatitis C: a cohort study of 1249 patients
    Kenji Ikeda
    Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    Dig Dis Sci 51:603-9. 2006
    ....
  5. ncbi Substitution of amino acid 70 in the hepatitis C virus core region of genotype 1b is an important predictor of elevated alpha-fetoprotein in patients without hepatocellular carcinoma
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    J Med Virol 80:1354-62. 2008
    ..The results highlight the importance of eradication of mutant type virus of aa 70 for reducing the risk of hepatocarcinogenesis...
  6. ncbi A matched case-controlled study of 48 and 72 weeks of peginterferon plus ribavirin combination therapy in patients infected with HCV genotype 1b in Japan: amino acid substitutions in HCV core region as predictor of sustained virological response
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    J Med Virol 81:452-8. 2009
    ..Substitution of aa 70 and 91 is also a useful pretreatment predictor of response to 72-week PEG-IFN/RBV...
  7. ncbi Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C
    Yasuji Arase
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Hepatology 49:739-44. 2009
    ..10; 95% CI 1.38-3.18; P < 0.001). CONCLUSION: Our results indicate sustained virological response causes a two-thirds reduction in the risk of type 2 diabetes development in HCV-positive patients treated with IFN...
  8. ncbi Clinicopathological features, background liver disease, and survival analysis of HCV-positive patients with hepatocellular carcinoma: differences between young and elderly patients
    Hiromi Saneto
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    J Gastroenterol 43:975-81. 2008
    ..The aim of this retrospective study was to determine the incidence and characteristics of hepatocellular carcinoma (HCC) in hepatitis C virus (HCV) antibody-positive elderly patients with chronic hepatitis without cirrhosis...
  9. ncbi Prediction of response to pegylated interferon and ribavirin in hepatitis C by polymorphisms in the viral core protein and very early dynamics of viremia
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Intervirology 50:361-8. 2007
    ..To evaluate power of amino acid polymorphisms in core protein of hepatitis C virus (HCV) for predicting sustained virological response (SVR) to pegylated interferon (Peg-IFN)/ribavirin, when they were combined with virological response...
  10. ncbi Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy
    Norio Akuta
    Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    Intervirology 48:372-80. 2005
    ..Non-virological responders (NVRs, namely ultimate resistant cases) who do not achieve HCV-RNA negativity during treatment are also encountered. We investigated the pretreatment virological features of NVRs...
  11. ncbi Virological response and hepatocarcinogenesis in lamivudine-resistant hepatitis B virus genotype C patients treated with lamivudine plus adefovir dipivoxil
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Intervirology 51:385-93. 2008
    ..The long-term efficacy of adefovir dipivoxil in combination with lamivudine to chronic hepatitis B virus (HBV) infection is still unclear...
  12. ncbi Lamivudine monotherapy for spontaneous severe acute exacerbation of chronic hepatitis B
    Akihito Tsubota
    Department of Gastroenterology, Toranomon Hospital, Minato, Tokyo, Japan
    J Gastroenterol Hepatol 20:426-32. 2005
    ..The purpose of the present paper was to identify factors that could influence the rapid progression of liver disease to hepatic failure, and assess the effects of lamivudine on serious disease...
  13. ncbi Necessities of interferon therapy in elderly patients with chronic hepatitis C
    Kenji Ikeda
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Am J Med 122:479-86. 2009
    ..The significance of antiviral therapy for elderly patients with chronic hepatitis C virus (HCV) infection has not been elucidated...
  14. ncbi HBcrAg is a predictor of post-treatment recurrence of hepatocellular carcinoma during antiviral therapy
    Tetsuya Hosaka
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Liver Int 30:1461-70. 2010
    ....
  15. ncbi Efficacy of switching to entecavir monotherapy in Japanese lamivudine-pretreated patients
    Fumitaka Suzuki
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    J Gastroenterol Hepatol 25:892-8. 2010
    ..To assess the efficacy of switching Japanese chronic hepatitis B patients from lamivudine monotherapy to entecavir 0.5 mg/day...
  16. ncbi Long-term outcome after interferon therapy in elderly patients with chronic hepatitis C
    Yasuji Arase
    Department of Gastroenterology, and Hepatic Research Unit, Toranomon Hospital, Toranomon, Tokyo, Japan
    Intervirology 50:16-23. 2007
    ..The purpose of this study was to elucidate the long-term outcome after interferon (IFN) therapy in chronic hepatitis C elderly patients...
  17. ncbi Influence of amino-acid polymorphism in the core protein on progression of liver disease in patients infected with hepatitis C virus genotype 1b
    Mariko Kobayashi
    Research Institute for Hepatology, Toranomon Hospital, Tokyo, Japan
    J Med Virol 82:41-8. 2010
    ....
  18. ncbi Interferon lowers tumor recurrence rate after surgical resection or ablation of hepatocellular carcinoma: a pilot study of patients with hepatitis B virus-related cirrhosis
    Takashi Someya
    Department of Hepatology, Toranomon Hospital, 2-2-2 Toranomon, Minato-ku, Tokyo 105-8470, Japan
    J Gastroenterol 41:1206-13. 2006
    ..21, P = 0.037) even after adjusting for background characteristics. CONCLUSIONS: IFN was inferred to decrease tumor recurrence after treatment of HCC in patients with HBV-related cirrhosis, especially in the subgroup with high AST...
  19. ncbi Efficacy of low-dose intermittent interferon-alpha monotherapy in patients infected with hepatitis C virus genotype 1b who were predicted or failed to respond to pegylated interferon plus ribavirin combination therapy
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    J Med Virol 80:1363-9. 2008
    ....
  20. ncbi Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load
    Norio Akuta
    Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    J Med Virol 78:83-90. 2006
    ....
  21. ncbi Comparison of interferon and lamivudine treatment in Japanese patients with HBeAg positive chronic hepatitis B
    Yasuji Arase
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    J Med Virol 79:1286-92. 2007
    ..002). Our results suggest that (1) IFN and LMV are the similar effect on response, (2) IFN therapy is more effective for younger patients...
  22. ncbi An open pilot study exploring the efficacy of fluvastatin, pegylated interferon and ribavirin in patients with hepatitis C virus genotype 1b in high viral loads
    Hitomi Sezaki
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Intervirology 52:43-8. 2009
    ..Response to pegylated (PEG) interferon (IFN) and ribavirin is achieved only in 40-50% of patients infected with hepatitis C virus (HCV) of genotype 1 in high viral loads, which needs to be improved...
  23. ncbi Amino acid substitutions in the hepatitis C virus core region of genotype 1b affect very early viral dynamics during treatment with telaprevir, peginterferon, and ribavirin
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    J Med Virol 82:575-82. 2010
    ....
  24. ncbi Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol l
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    J Hepatol 46:403-10. 2007
    ..Here, we determined the predictive factors of sustained virological response (SVR) and early virologic response (EVR) to this treatment...
  25. ncbi Efficacy of entecavir treatment for lamivudine-resistant hepatitis B over 3 years: histological improvement or entecavir resistance?
    Yoshiyuki Suzuki
    Department of Hepatology, Toranomon Hospital, Takatsu ku, Kawasaki City, Japan
    J Gastroenterol Hepatol 24:429-35. 2009
    ..However, hepatitis B virus (HBV) mutants resistant to lamivudine emerge frequently accompanied by breakthrough hepatitis...
  26. ncbi Amino acid substitution in HCV core region and genetic variation near the IL28B gene affect viral dynamics during telaprevir, peginterferon and ribavirin treatment
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Intervirology 55:417-25. 2012
    ....
  27. ncbi Diabetes enhances hepatocarcinogenesis in noncirrhotic, interferon-treated hepatitis C patients
    Yusuke Kawamura
    Department of Hepatology, Toranomon Hospital, Minato ku, Tokyo, Japan
    Am J Med 123:951-956.e1. 2010
    ..This retrospective cohort study assessed the impact of diabetes mellitus on hepatocarcinogenesis and determined the predictors of hepatocarcinogenesis in noncirrhotic, interferon-treated patients with hepatitis C virus infection...
  28. ncbi Clinical and virological features of non-breakthrough and severe exacerbation due to lamivudine-resistant hepatitis B virus mutants
    Fumitaka Suzuki
    Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    J Med Virol 78:341-52. 2006
    ..More substitutions in the rt region and the other proteins may be related to the emergence of severe hepatitis caused by lamivudine-resistant virus...
  29. ncbi Amino acid substitutions in the hepatitis C virus core region are the important predictor of hepatocarcinogenesis
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Hepatology 46:1357-64. 2007
    ..In multicourse IFN therapy to nondouble wild-type, we emphasize the importance of reducing the risk of hepatocarcinogenesis by mean ALT during an IFN-free period below 1.5 times the upper limit of normal...
  30. ncbi Efficacy in patients with dose reduction in combination therapy of peginterferon and ribavirin for chronic hepatitis C
    Yasuji Arase
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Intervirology 51:1-6. 2008
    ..The aim of this study was to elucidate efficacy after dose reduction in combination therapy of peginterferon and ribavirin for chronic hepatitis C...
  31. ncbi Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up
    Hiromi Yatsuji
    Department of Hepatology, Toranomon Hospital, 2 2 2 Toranomon, Minato ku, Tokyo 105 8470, Japan
    J Hepatol 48:923-31. 2008
    ..We studied the long-term efficacy (median follow-up of 28 months) of adefovir (ADV) in combination with lamivudine (LAM) in 132 LAM-resistant Japanese patients with chronic genotype C-dominant hepatitis B virus (HBV) infection...
  32. ncbi Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Hepatology 52:421-9. 2010
    ....
  33. ncbi Recurrence rate and prognosis of patients with hepatocellular carcinoma that developed after elimination of hepatitis C virus RNA by interferon therapy. A closed cohort study including matched control patients
    Kenji Ikeda
    Department of Gastroenterology, Toranomon Hospital, and Okinaka Memorial Institute for Medical Research, Tokyo, Japan
    Oncology 65:204-10. 2003
    ..Although hepatocellular carcinoma does develop after sustained response to interferon (IFN) in patients with chronic hepatitis C, details on the clinical prognosis have not been elucidated yet...
  34. ncbi Factors associated with the virological response of lamivudine-resistant hepatitis B virus during combination therapy with adefovir dipivoxil plus lamivudine
    Tetsuya Hosaka
    Department of Gastroenterology, Toranomon Hospital, 2 2 2 Toranomon, Tokyo 105 8470, Japan
    J Gastroenterol 42:368-74. 2007
    ..The aim of this study was to investigate the factors associated with the response of lamivudine-resistant hepatitis B virus (HBV) during combination therapy with adefovir dipivoxil plus lamivudine...
  35. ncbi Amino acid substitutions in hepatitis C virus core region predict hepatocarcinogenesis following eradication of HCV RNA by antiviral therapy
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    J Med Virol 83:1016-22. 2011
    ..This study emphasizes the importance of detection of aa substitutions in the core region before antiviral therapy...
  36. ncbi Virological and biochemical relapse after discontinuation of lamivudine monotherapy for chronic hepatitis B in Japan: comparison with breakthrough hepatitis during long-term treatment
    Norio Akuta
    Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    Intervirology 48:174-82. 2005
    ..CONCLUSION: Our results in Japanese patients with genotype C-dominant hepatitis B suggest that discontinuation of lamivudine monotherapy, and retreatment after the emergence of YMDD mutant should be given attention...
  37. ncbi Efficacy of interferon monotherapy in young adult patients with chronic hepatitis C virus infection
    Kiminori Uka
    Department of Gastroenterology, Toranomon Hospital, Minato-ku, Tokyo, Japan
    J Gastroenterol 41:470-5. 2006
    ..Long-term IFN monotherapy may be suitable for young women who desire to become pregnant or those with anemia...
  38. ncbi Association of HLA-DR14 with the treatment response in Japanese patients with autoimmune hepatitis
    Yoshiyuki Suzuki
    Department of Hepatology, Toranomon Hospital, Takatsu ku, Kawasaki City, Japan
    Dig Dis Sci 55:2070-6. 2010
    ..Influence of human lymphocyte antigen (HLA) on the therapeutic response in autoimmune hepatitis (AIH) is not known...
  39. ncbi Efficacy of lamivudine therapy and factors associated with emergence of resistance in chronic hepatitis B virus infection in Japan
    Fumitaka Suzuki
    Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    Intervirology 46:182-9. 2003
    ..However, the patient cohorts in such studies are relatively small...
  40. ncbi Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 2a high viral load and virological response to interferon-ribavirin combination therapy
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo 105 0001, Japan
    Intervirology 52:301-9. 2009
    ....
  41. ncbi Interferon monotherapy for patients with chronic hepatitis C and normal serum aminotransferase levels at commencement of treatment
    Satoshi Mamori
    Department of Gastroenterology, Toranomon Hospital, 2-2-2 Toranomon, Minato-ku, 105-8470 Tokyo, Japan
    J Gastroenterol 39:776-82. 2004
    ..CONCLUSIONS: Our data suggest that IFN therapy is effective for patients with normal ALT levels and less than 1 Meq/ml HCV-RNA. Thus, such patients should be considered for curative IFN therapy...
  42. ncbi The influence of hepatitis B virus genotype on the development of lamivudine resistance during long-term treatment
    Norio Akuta
    Department of Gastroenterology, Toranomon Hospital, 2 2 2 Toranomon, Minato ku, Tokyo 105 0001, Japan
    J Hepatol 38:315-21. 2003
    ..Genotype-dependent development of lamivudine resistance in hepatitis B virus (HBV) has not been reported...
  43. ncbi Anticarcinogenic impact of interferon on patients with chronic hepatitis C: a large-scale long-term study in a single center
    Kenji Ikeda
    Department of Gastroenterology, Toranomon Hospital, Toranomon 2 2 2, Minato ku, Tokyo 105 8470, Japan
    Intervirology 49:82-90. 2006
    ..The anticarcinogenic capacity of interferon (IFN) was assessed in a cohort of Japanese patients with chronic hepatitis C en masse...
  44. ncbi High-dose interferon alpha-2b induction therapy in combination with ribavirin for Japanese patients infected with hepatitis C virus genotype 1b with a high baseline viral load
    Akihito Tsubota
    Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    J Gastroenterol 39:155-61. 2004
    ....
  45. ncbi Early viral kinetics and treatment outcome in combination of high-dose interferon induction vs. pegylated interferon plus ribavirin for naive patients infected with hepatitis C virus of genotype 1b and high viral load
    Akihito Tsubota
    Department of Gastroenterology, Toranomon Hospital, Minato ku, Tokyo, Japan
    J Med Virol 75:27-34. 2005
    ..919. The results suggest that early monitoring of viral kinetics is a useful measure to predict virological response, and might facilitate development of rational and effective therapeutic strategies...
  46. ncbi Poor response to pegylated interferon and ribavirin in older women infected with hepatitis C virus of genotype 1b in high viral loads
    Hitomi Sezaki
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Dig Dis Sci 54:1317-24. 2009
    ..Response to treatment in patients with chronic hepatitis C, with reference to age and gender, has not been examined fully...
  47. ncbi Long-term follow-up of interferon monotherapy in 454 consecutive naive patients infected with hepatitis C virus: multi-course interferon therapy may reduce the risk of hepatocellular carcinoma and increase survival
    Norio Akuta
    Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    Scand J Gastroenterol 40:688-96. 2005
    ..The long-term effects of multi-course interferon (IFN) monotherapy in patients infected with hepatitis C virus (HCV) are still unclear...
  48. ncbi Favorable efficacy of long-term lamivudine therapy in patients with chronic hepatitis B: an 8-year follow-up study
    Norio Akuta
    Department of Gastroenterology, Toranomon Hospital, 2 2 2 Toranomon, Minato ku, Tokyo 105 0001, Japan
    J Med Virol 75:491-8. 2005
    ..None developed cirrhosis or hepatocellular carcinoma (HCC) during follow-up. Our results suggest that long-term lamivudine therapy improves long-term prognosis, especially when additional treatment for breakthrough hepatitis is used...
  49. ncbi Hepatocyte steatosis is an important predictor of response to interferon (IFN) monotherapy in Japanese patients infected with HCV genotype 2a: Virological features of IFN-resistant cases with hepatocyte steatosis
    Norio Akuta
    Department of Gastroenterology, Toranomon Hospital, 2 2 2 Toranomon, Minato ku, Tokyo 105 0001, Japan
    J Med Virol 75:550-8. 2005
    ..Further large-scale studies are warranted to examine the role of amino acid substitutions on IFN resistance specific for steatosis...
  50. ncbi Persistence of acute infection with hepatitis B virus genotype A and treatment in Japan
    Yoshiyuki Suzuki
    Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    J Med Virol 76:33-9. 2005
    ..Infection was cleared in only one of the six (17%) patients who received antiviral therapy...
  51. ncbi Response to long-term lamivudine treatment in patients infected with hepatitis B virus genotypes A, B, and C
    Mariko Kobayashi
    Research Institute for Hepatology, Toranomon Hospital, Tokyo, Japan
    J Med Virol 78:1276-83. 2006
    ..36], P = 0.03); it was influenced by genotypes only in patients with HBeAg. In conclusion, HBV genotypes help in predicting response to long-term lamivudine treatment and development of YMDD mutants in patients with chronic hepatitis B...
  52. ncbi Complicated relationships of amino acid substitution in hepatitis C virus core region and IL28B genotype influencing hepatocarcinogenesis
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, and Okinaka Memorial Institute for Medical Research, Tokyo, Japan
    Hepatology 56:2134-41. 2012
    ..The IL28B genotype might partly affect changes over time of dominant amino acid in core aa 70 of HCV-1b...
  53. ncbi Long-term follow-up of HBeAg-positive young adult Japanese patients treated with corticosteroid withdrawal therapy for chronic hepatitis B
    Hitomi Sezaki
    Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    Intervirology 49:339-45. 2006
    ..To evaluate the long-term effects of corticosteroid withdrawal therapy (CSWT) in young adult Japanese patients with chronic hepatitis B (CH-B) virus infection...
  54. ncbi The efficacy of 24-week interferon monotherapy for type C liver cirrhosis in Japanese patients with genotype 1b and low virus load
    Yasuji Arase
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Intervirology 51:265-9. 2008
    ..The aim of this study was to elucidate the efficacy of interferon (IFN) therapy in liver cirrhosis Japanese patients with genotype 1b and low virus load...
  55. ncbi Interferon-alpha for reinfection with hepatitis C virus in two patients with chronic hepatitis C who had responded to previous therapies
    Norio Akuta
    Division of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    Dig Dis Sci 48:1654-7. 2003
  56. ncbi Inhibitory effect of branched-chain amino acid granules on progression of compensated liver cirrhosis due to hepatitis C virus
    Masahiro Kobayashi
    Department of Gastroenterology, Toranomon Hospital, 2 2 2 Toranomon, Minato ku, Tokyo, 105 8470, Japan
    J Gastroenterol 43:63-70. 2008
    ..A phase II randomized controlled trial was conducted in patients with compensated liver cirrhosis to investigate the inhibitory effect of branched-chain amino acid (BCAA) granules for oral use (TK-98) on disease progression...
  57. ncbi Efficacy of 6-month interferon therapy in chronic hepatitis B virus infection in Japan
    Fumitaka Suzuki
    Department of Gastroenterology, Toranomon Hospital, 2-2-2 Toranomon, Minato-ku, 105-8470, Tokyo, Japan
    J Gastroenterol 39:969-74. 2004
    ..CONCLUSIONS: The response rate to 6-month IFN therapy among HBeAg-positive patients was low. However, young patients may require long-term IFN therapy...
  58. ncbi Virological outcomes in patients infected chronically with hepatitis B virus genotype A in comparison with genotypes B and C
    Mariko Kobayashi
    Research Institute for Hepatology, Toranomon Hospital, Tokyo, Japan
    J Med Virol 78:60-7. 2006
    ..In conclusion, patients persistently infected with HBV genotype A fare better than those with genotype B or C. However, high levels of HBV DNA continue in those in whom HBeAg persists along with fibrosis in the liver...
  59. ncbi Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir
    Fumitaka Suzuki
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Hepatology 53:415-21. 2011
    ..With careful monitoring of anemia and prompt adjustment of RBV dose, SVR can be achieved comparably frequently between patients with CC and CA/AA genotypes...
  60. ncbi Hepatitis B virus-related hepatocellular carcinogenesis and its prevention
    Kenji Ikeda
    Department of Gastroenterology, Toranomon Hospital, Tokyo, and Okinaka Memorial Institute for Medical Research, Tokyo, Japan
    Intervirology 48:29-38. 2005
    ..026). A significant decrease or loss of serum HBV-DNA stops HCC development, and its sequential analysis could be very useful both in the prediction and early detection of small HCC...
  61. ncbi Long-term outcome of HBV carriers with negative HBe antigen and normal aminotransferase
    Kenji Ikeda
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Am J Med 119:977-85. 2006
    ..To elucidate the incidence of hepatitis activation and hepatocellular carcinogenesis in patients with negative HBe antigen and normal aminotransferase, long-term observation was performed in a retrospective cohort...
  62. ncbi Long-term presence of HBV in the sera of chronic hepatitis B patients with HBsAg seroclearance
    Yasuji Arase
    Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    Intervirology 50:161-5. 2007
    ..The aim of this study was to elucidate the presence of serum hepatitis B virus (HBV) DNA at a prolonged time after seroclearance of hepatitis B surface antigen (HBsAg)...
  63. ncbi Natural history of compensated cirrhosis in the Child-Pugh class A compared between 490 patients with hepatitis C and 167 with B virus infections
    Masahiro Kobayashi
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    J Med Virol 78:459-65. 2006
    ....
  64. ncbi HBe antigen loss during lamivudine therapy is not caused by mutations in precore and core promoter genes in patients with chronic hepatitis B
    Fumitaka Suzuki
    Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    J Med Virol 70:355-60. 2003
    ..Our data suggested that during lamivudine therapy, core promoter and precore mutations do not influence HBeAg loss or seroconversion but may reduce the viral level upon HBeAg loss or seroconversion...
  65. ncbi Efficacy of interferon monotherapy to 394 consecutive naive cases infected with hepatitis C virus genotype 2a in Japan: therapy efficacy as consequence of tripartite interaction of viral, host and interferon treatment-related factors
    Norio Akuta
    Division of Gastroenterology, Toranomon Hospital, 2 2 2 Toranomon, Minato ku, Tokyo 105 0001, Japan
    J Hepatol 37:831-6. 2002
    ..The mechanism of variable response to interferon (IFN) monotherapy in patients infected with HCV genotype 2a is still unclear. Here we investigated the response in a large group of patients infected with genotype 2a...
  66. ncbi Significance of multicentric cancer recurrence after potentially curative ablation of hepatocellular carcinoma: a longterm cohort study of 892 patients with viral cirrhosis
    Kenji Ikeda
    Department of Gastroenterology, Toranomon Hospital, 2-2-2 Toranomon, Minato-ku, Tokyo 105-8470, Japan
    J Gastroenterol 38:865-76. 2003
    ....
  67. ncbi Influence of hepatitis C virus subtype on hepatocellular carcinogenesis: a multivariate analysis of a retrospective cohort of 593 patients with cirrhosis
    Kenji Ikeda
    Department of Gastroenterology, Toranomon Hospital, and the Memorial Institute for Medical Research, Tokyo, Japan
    Intervirology 45:71-8. 2002
    ..The influence of hepatitis C virus (HCV) subtypes on hepatocellular carcinogenesis was prospectively investigated...
  68. ncbi Significance of hepatitis B virus DNA clearance and early prediction of hepatocellular carcinogenesis in patients with cirrhosis undergoing interferon therapy: long-term follow up of a pilot study
    Kenji Ikeda
    Department of Gastroenterology, Toranomon Hospital and Okinaka Memorial Institute for Medical Research, Tokyo, Japan
    J Gastroenterol Hepatol 20:95-102. 2005
    ..Because the anti-carcinogenic effect and mechanism of interferon (IFN) in patients with hepatitis B virus (HBV)-related cirrhosis have not been elucidated, quantitative analysis of HBV-DNA concentration was carried out sequentially...
  69. ncbi Viral elimination reduces incidence of malignant lymphoma in patients with hepatitis C
    Yusuke Kawamura
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Am J Med 120:1034-41. 2007
    ..The aim of this retrospective study was to determine the incidence of malignant lymphoma and the relationship between malignant lymphoma and viral elimination in patients with HCV...
  70. ncbi Dysplastic nodules frequently develop into hepatocellular carcinoma in patients with chronic viral hepatitis and cirrhosis
    Masahiro Kobayashi
    Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    Cancer 106:636-47. 2006
    ..Advances in imaging technology have enhanced the detection of small nodular lesions during the course of chronic liver disease...
  71. ncbi Consistently low hepatitis B virus DNA saves patients from hepatocellular carcinogenesis in HBV-related cirrhosis. A nested case-control study using 96 untreated patients
    Kenji Ikeda
    Department of Gastroenterology, Toranomon Hospital, and Okinaka Memorial Institute for Medical Research, Tokyo, Japan
    Intervirology 46:96-104. 2003
    ..To elucidate the influence of serum hepatitis B virus (HBV) load on hepatocellular carcinogenesis in cirrhotic patients, HBV-DNA was sequentially measured...
  72. ncbi Multivariate analysis of risk factors for the development of type 2 diabetes in nonalcoholic fatty liver disease
    Yasuji Arase
    Department of Hepatology, Toranomon Hospital, 2 2 2 Toranomon, Minato ku, Tokyo 105 8470, Japan
    J Gastroenterol 44:1064-70. 2009
    ..The aim of this retrospective cohort study was to assess the cumulative development of type 2 diabetes and predictive factors for its development in Japanese patients with NAFLD...
  73. ncbi Development of hepatocellular carcinoma in elderly patients with chronic hepatitis C with or without elevated aspartate and alanine aminotransferase levels
    Mariko Kobayashi
    Research Institute for Hepatology, Toranomon Hospital, Tokyo, Japan
    Scand J Gastroenterol 44:975-83. 2009
    ..The purpose of the study was to define the natural history of elderly patients with chronic hepatitis C needs in order to prevent HCC from arising in these patients...
  74. ncbi Amino acid substitutions in the hepatitis C virus core region of genotype 1b are the important predictor of severe insulin resistance in patients without cirrhosis and diabetes mellitus
    Norio Akuta
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    J Med Virol 81:1032-9. 2009
    ....
  75. ncbi Hepatocellular carcinoma in noncirrhotic young adult patients with chronic hepatitis B viral infection
    Hitomi Sezaki
    Department of Gastroenterology, Toranomon Hospital, 2-2-2 Toranomon, Minato-ku, 105-8470, Tokyo, Japan
    J Gastroenterol 39:550-6. 2004
    ....
  76. ncbi [Current status of treatment for HBV-related cirrhosis]
    Kenji Ikeda
    Department of Gastroenterology, Toranomon Hospital
    Nippon Rinsho 62:358-62. 2004
  77. ncbi Stepwise hook extension technique for radiofrequency ablation therapy of hepatocellular carcinoma
    Masahiro Kobayashi
    Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    Oncology 63:139-44. 2002
    ..Our study was designed to examine the efficacy of stepwise hook extension technique for radiofrequency ablation (RFA) therapy of hepatocellular carcinoma in a randomized controlled study...
  78. ncbi High serum des-gamma-carboxy prothrombin level predicts poor prognosis after radiofrequency ablation of hepatocellular carcinoma
    Masahiro Kobayashi
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Cancer 115:571-80. 2009
    ..Radiofrequency ablation (RFA) has been an alternative choice for unresectable HCC. However, RFA is expected to have similar therapeutic efficacy for early stage HCC with fewer invasions...
  79. ncbi [Strategy for advanced hepatocellular carcinoma unresponsive to transcatheter arterial chemoembolization using epirubicin]
    Yusuke Kawamura
    Dept of Hepatology, Toranomon Hospital, Minato ku, Tokyo, Japan
    Gan To Kagaku Ryoho 37:402-7. 2010
    ..However, the results of our study suggested the advantage of using platinum derivatives in patients with TACE-resistant HCC...
  80. ncbi Predictive factors of advanced recurrence after curative resection of small hepatocellular carcinoma
    Tetsuya Hosaka
    Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    Liver Int 29:736-42. 2009
    ..The advanced patterns of recurrence occasionally occur after resection. In this study, we analysed the clinical and histological characteristics of small HCC and evaluated the predictive factors of advanced tumour recurrence...
  81. ncbi Virological and biochemical features in elderly HCV patients with hepatocellular carcinoma: amino acid substitutions in HCV core region as predictor of mortality after first treatment
    Suguru Ogura
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    Intervirology 52:179-88. 2009
    ..The aim of this study was to evaluate the impact of core aa substitutions on mortality in elderly patients...
  82. ncbi Effect of acute self-limited hepatitis C virus (HCV) superinfection on hepatitis B virus (HBV)-related cirrhosis. Virological features of HBV-HCV dual infection
    Norio Akuta
    Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    Dig Dis Sci 49:281-8. 2004
    ..Our results suggest that the impact of acute HCV infection on chronic HBV infection varies according to HBV virological state...
  83. ncbi Interferon therapy for 2 years or longer reduces the incidence of hepatocarcinogenesis in patients with chronic hepatitis C viral infection
    Yasuji Arase
    Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    Intervirology 47:355-61. 2004
    ....
  84. ncbi Usefulness of the serum KL-6 assay in patients with hepatitis C virus
    Yasuji Arase
    Department of Gastroenterology and Hepatic Research Unit, Toranomon Hospital, Tokyo, Japan
    Intervirology 48:400-4. 2005
    ..The aim of this study is to evaluate the serum level of KL-6 in hepatitis C virus (HCV)-positive patients with chronic liver disease...
  85. ncbi Randomized controlled trial for the efficacy of hepatic arterial occlusion during radiofrequency ablation for small hepatocellular carcinoma--direct ablative effects and a long-term outcome
    Masahiro Kobayashi
    Department of Hepatology, Toranomon Hospital, Tokyo, the Okinaka Memorial Institute for Medical Research, Tokyo, Japan
    Liver Int 27:353-9. 2007
    ..To evaluate the efficacy of temporary balloon arterial occlusion during radiofrequency ablation (RFA), randomized controlled trial was performed...
  86. ncbi Locoregional therapy for hepatocellular carcinoma
    Kenji Ikeda
    Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    Trop Gastroenterol 26:4-12. 2005
  87. ncbi Origin of neovascular structure in an early stage of hepatocellular carcinoma: study of alpha-smooth muscle actin immunohistochemistry in serial thin sections of surgically resected cancer
    Kenji Ikeda
    Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    J Gastroenterol Hepatol 21:183-90. 2006
    ..To elucidate the origin of the neovascular structure found in well-differentiated hepatocellular carcinoma (HCC), an immunohistochemical study was performed on sequential thin section specimens...
  88. ncbi Diabetes mellitus worsens the recurrence rate after potentially curative therapy in patients with hepatocellular carcinoma associated with nonviral hepatitis
    Yusuke Kawamura
    Department of Hepatology, Toranomon Hospital, Tokyo, Japan
    J Gastroenterol Hepatol 23:1739-46. 2008
    ..The aim of this retrospective study was to examine the relationship between diabetes mellitus and recurrence of hepatocellular carcinoma after potentially curative therapy for hepatocellular carcinoma with nonviral hepatitis...
  89. ncbi Hepatitis C virus enhances incidence of idiopathic pulmonary fibrosis
    Yasuji Arase
    Department of Hepatology, Toranomon Hospital, Minato ku, Tokyo 105 8470, Japan
    World J Gastroenterol 14:5880-6. 2008
    ..To investigate the cumulative development incidence and predictive factors for idiopathic pulmonary fibrosis in hepatitis C virus (HCV) positive patients...
  90. ncbi Viral genotypes and response to interferon in patients with acute prolonged hepatitis B virus infection of adulthood in Japan
    Mariko Kobayashi
    Research Institute for Hepatology, Toranomon Hospital, Tokyo, Japan
    J Med Virol 68:522-8. 2002
    ....
  91. ncbi Efficacy of lamivudine treatment in Japanese patients with hepatitis B virus-related cirrhosis
    Hiromi Ooga
    Department of Gastroenterology, Toranomon Hospital, 2-2-2 Toranomon, Minato-ku, 105-8470, Tokyo, Japan
    J Gastroenterol 39:1078-84. 2004
    ..CONCLUSIONS: Lamivudine therapy improved the clinical course in some cirrhotic patients. However, in patients with Child's B and C cirrhosis, the emergence of YMDD mutants sometimes led to deterioration of liver function...
  92. ncbi Prolonged-efficacy of bisphosphonate in postmenopausal women with osteoporosis and chronic liver disease
    Yasuji Arase
    Department of Hepatology, Toranomon Hospital, Minato ku, Tokyo, Japan
    J Med Virol 80:1302-7. 2008
    ..2% at the second year, and 57.6% at the fifth year. The present study suggests that a serum albumin level of >or=3.5 g/dl and cyclic etidronate treatment reduce the appearance of bone fracture...
  93. ncbi Association of amino acid substitution pattern in nonstructural protein 5A of hepatitis C virus genotype2a low viral load and response to interferon monotherapy
    Norio Akuta
    Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    J Med Virol 69:376-83. 2003
    ..Our results suggest that substitution patterns in NS5A in patients with low titer of HCV genotype 2a may affect their response to IFN, but the response to therapy may be affected by mechanisms other than substitutions in this region...
  94. ncbi Natural histories of hepatitis C virus infection in men and women simulated by the Markov model
    Junko Tanaka
    The Department of Infectious Disease and Control, Hiroshima University Graduate School of Biomedical Sciences, Hiroshima, Japan
    J Med Virol 70:378-86. 2003
    ..The Markov simulation would help in assessing the long-term outcome of HCV infection and making decisions in the management of HCV carriers toward prevention of hepatocellular carcinoma...
  95. ncbi Long-term clinical outcome and effect of glycyrrhizin in 1093 chronic hepatitis C patients with non-response or relapse to interferon
    Bart J Veldt
    Department of Gastroenterology and Hepatology, Erasmus Medical Center Rotterdam, The Netherlands
    Scand J Gastroenterol 41:1087-94. 2006
    ....
  96. ncbi Benefit of lamivudine therapy and factors associated with clinical outcome in spontaneous severe acute exacerbation of chronic hepatitis B virus infection
    Akihito Tsubota
    Institute of Clinical Medicine and Research, Jikei University School of Medicine, Chiba, Japan
    Intervirology 47:335-41. 2004
    ..The aim of this study was to clarify potential factors, including benefit of lamivudine therapy, which could influence clinical course of the serious disease in an area of intermediate HBV endemicity...
  97. ncbi Prolonged-interferon therapy reduces hepatocarcinogenesis in aged-patients with chronic hepatitis C
    Yasuji Arase
    Department of Gastroenterology, Toranomon Hospital, 2 2 2 Toranomon, Minato ku, Tokyo, Japan
    J Med Virol 79:1095-102. 2007
    ..9 compared with mild or moderate fibrosis. In conclusion, long-term IFN therapy for aged patients with chronic HCV infection is effective in decreasing the serum AFP level and preventing hepatocarcinogenesis...
  98. ncbi Long-term outcome after hepatitis B surface antigen seroclearance in patients with chronic hepatitis B
    Yasuji Arase
    Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    Am J Med 119:71.e9-16. 2006
    ..The aim of this study was to elucidate the long-term outcome after hepatitis B surface antigen (HBsAg) seroclearance in a large number of Japanese patients...
  99. ncbi Side effects of combination therapy of peginterferon and ribavirin for chronic hepatitis-C
    Yasuji Arase
    Department of Hepatology, Toranomon Hospital, Tokyo
    Intern Med 46:1827-32. 2007
    ..The aim of this study was to elucidate the side effects after combination therapy of peginterferon and ribavirin for Japanese patients with chronic hepatitis C...
  100. ncbi Parkinson's disease mimicking senile dementia of the Alzheimer type: a clinicopathological study of four autopsy cases
    Kuniaki Tsuchiya
    Department of Laboratory Medicine and Pathology, Tokyo Metropolitan Matsuzawa Hospital, Japan
    Neuropathology 22:77-84. 2002
    ..Furthermore, we postulate that the clinical features of PD are more widespread than previously believed...
  101. ncbi Sustained negativity for HCV-RNA over 24 or more months by long-term interferon therapy correlates with eradication of HCV in patients with hepatitis C virus genotype 1b and high viral load
    Yasuji Arase
    Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan
    Intervirology 47:19-25. 2004
    ..We assessed whether sustained negativity for HCV-RNA over 24 or more months by long-term interferon (IFN) therapy correlates with eradication of HCV in patients with hepatitis C virus genotype 1b and high viral load or not...